Trials / Conditions / T-Cell Prolymphocytic Leukemia

T-Cell Prolymphocytic Leukemia

19 registered clinical trials studyying T-Cell Prolymphocytic Leukemia — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocy NCT07311746	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma NCT07356245	Jonathan Brammer	Phase 2
Recruiting	Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT06810778	Jonsson Comprehensive Cancer Center	Phase 1 / Phase 2
Recruiting	Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymp NCT06420076	Essen Biotech	Phase 1 / Phase 2
Active Not Recruiting	Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T- NCT05377827	Washington University School of Medicine	Phase 1
Recruiting	A Registry for People With T-cell Lymphoma NCT05978141	Memorial Sloan Kettering Cancer Center	—
Active Not Recruiting	Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients NCT05823571	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 1
Recruiting	Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CM NCT04771572	Newave Pharmaceutical Inc	Phase 1
Recruiting	A Study of Ruxolitinib and Duvelisib in People With Lymphoma NCT05010005	Memorial Sloan Kettering Cancer Center	Phase 1
Completed	Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Trea NCT04312841	Ohio State University Comprehensive Cancer Center	Phase 2
Completed	Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia NCT03989466	M.D. Anderson Cancer Center	Phase 1
Completed	Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chr NCT02689453	National Cancer Institute (NCI)	Phase 1
Unknown	CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma NCT02742727	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	Phase 1 / Phase 2
Completed	Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patient NCT01251575	Fred Hutchinson Cancer Center	Phase 2
Completed	Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) NCT01186640	German CLL Study Group	Phase 2
Completed	Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients NCT01008462	Fred Hutchinson Cancer Center	Phase 2
Completed	A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) NCT00749502	Tesaro, Inc.	Phase 1
Completed	Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treatin NCT00060424	Fred Hutchinson Cancer Center	Phase 2
Completed	Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or R NCT00005803	Fred Hutchinson Cancer Center	Phase 1 / Phase 2